JP2022541254A5 - - Google Patents
Info
- Publication number
- JP2022541254A5 JP2022541254A5 JP2022502926A JP2022502926A JP2022541254A5 JP 2022541254 A5 JP2022541254 A5 JP 2022541254A5 JP 2022502926 A JP2022502926 A JP 2022502926A JP 2022502926 A JP2022502926 A JP 2022502926A JP 2022541254 A5 JP2022541254 A5 JP 2022541254A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875402P | 2019-07-17 | 2019-07-17 | |
| US62/875,402 | 2019-07-17 | ||
| PCT/IB2020/000634 WO2021009566A1 (en) | 2019-07-17 | 2020-07-16 | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541254A JP2022541254A (ja) | 2022-09-22 |
| JP2022541254A5 true JP2022541254A5 (enExample) | 2023-07-25 |
| JP7723652B2 JP7723652B2 (ja) | 2025-08-14 |
Family
ID=72145418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502926A Active JP7723652B2 (ja) | 2019-07-17 | 2020-07-16 | 多発性硬化症（ＭＳ）の治療のためのＮＬＰＲ３モジュレーターとしてのＮ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）－４，５，６，７－テトラヒドロベンゾフラン－２－スルホンアミド誘導体および関連化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12466800B2 (enExample) |
| EP (1) | EP3999496B1 (enExample) |
| JP (1) | JP7723652B2 (enExample) |
| CN (1) | CN114555571B (enExample) |
| AU (1) | AU2020312800B2 (enExample) |
| BR (1) | BR112022000878A2 (enExample) |
| CA (1) | CA3151865A1 (enExample) |
| IL (1) | IL289885B2 (enExample) |
| MX (1) | MX2022000646A (enExample) |
| WO (1) | WO2021009566A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| CN118475558A (zh) * | 2021-12-22 | 2024-08-09 | 瑞石生物医药有限公司 | 一种磺酰脲类化合物 |
| US20250388568A1 (en) * | 2022-07-06 | 2025-12-25 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| CN116283533B (zh) * | 2023-02-17 | 2024-02-23 | 华南理工大学 | 具有nlrp3抑制活性的鸡脚参酮a及其衍生物与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) * | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| UA126675C2 (uk) * | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) * | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| ES2927851T3 (es) | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US20230011652A1 (en) * | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| TWI894229B (zh) | 2020-03-16 | 2025-08-21 | 瑞士商諾華公司 | 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物 |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CL2022002490A1 (es) | 2020-03-16 | 2023-05-05 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
-
2020
- 2020-07-16 AU AU2020312800A patent/AU2020312800B2/en active Active
- 2020-07-16 CN CN202080064480.1A patent/CN114555571B/zh active Active
- 2020-07-16 EP EP20757941.8A patent/EP3999496B1/en active Active
- 2020-07-16 IL IL289885A patent/IL289885B2/en unknown
- 2020-07-16 JP JP2022502926A patent/JP7723652B2/ja active Active
- 2020-07-16 BR BR112022000878A patent/BR112022000878A2/pt unknown
- 2020-07-16 MX MX2022000646A patent/MX2022000646A/es unknown
- 2020-07-16 US US17/627,082 patent/US12466800B2/en active Active
- 2020-07-16 CA CA3151865A patent/CA3151865A1/en active Pending
- 2020-07-16 WO PCT/IB2020/000634 patent/WO2021009566A1/en not_active Ceased